9th World Congress on Rare Diseases and Orphan Drugs

17 – 18 June 2019

The organising committee are delighted to invite all the participants over the globe to attend “9th World Congress on Rare Diseases and Orphan Drugs”, which will be held during June 17-18, 2019 at Berlin, Germany which includes prompt Keynote Presentations, Special Sessions, Workshops, Symposiums, Oral talks, Poster Presentations and Exhibitions in the field of Rare Diseases and Orphan Drugs.

Rare Diseases refer to those medical aberrations which affect a very least number of the population. They are characterized by a wide diversity of disorders and symptoms that differs not only from disease to disease but also from individual to individual patient suffering from the same disease. About 80% of these disorders have predictable genetic origins while the others are the result of infections, allergies, neurological related and environmental causes. A medicinal product developed for the treatment of a Rare Disease is an Orphan Drug. Under regular market environments the pharmaceutical industry has little attention in evolving and marketing products of Orphan Drugs proposed for only a small number of patients.

The conference conquers implication when we look at the worldwide deaths due to Rare Diseases. The majority of around 800 million people with other Rare Diseases, including 100,000 children born with thalassaemia annually receive no treatment. There are major ethical quandaries in dealing with global health issues such as the treatment of Orphan and Rare Diseases.

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern